# Kraig Biocraft Laboratories, Inc.: financial statements, quarterly

KBLB · OTC · CIK 1413119 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kblb.md) · [Financials](/companies/kblb/financials.md) · [Filings](/companies/kblb/filings.md) · [Insiders](/companies/kblb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kblb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [39.1](/filings/0001493152-24-045153.md) | [72.6 d](/filings/0001641172-25-001238.md) | [29.4](/filings/0001641172-25-010985.md) | [49.4](/filings/0001493152-25-011968.md) | [25.0](/filings/0001493152-25-021953.md) | [60.6 d](/filings/0001493152-26-013630.md) | [23.9](/filings/0001493152-26-023130.md) | [63.9](/filings/0001493152-26-037818.md) | [9.2](/filings/0001493152-25-021953.md) | [68.8 d](/filings/0001493152-26-013630.md) | [66.7](/filings/0001493152-26-023130.md) | [64.4](/filings/0001493152-26-037818.md) |
| Operating income | $k | [(459)](/filings/0001493152-24-045153.md) | [(1,188) d](/filings/0001641172-25-001238.md) | [(449)](/filings/0001641172-25-010985.md) | [(1,486)](/filings/0001493152-25-011968.md) | [(424)](/filings/0001493152-25-021953.md) | [(716) d](/filings/0001493152-26-013630.md) | [(580)](/filings/0001493152-26-023130.md) | [(638)](/filings/0001493152-26-037818.md) | [(1,434)](/filings/0001493152-25-021953.md) | [(723) d](/filings/0001493152-26-013630.md) | [(826)](/filings/0001493152-26-023130.md) | [(703)](/filings/0001493152-26-037818.md) |
| Interest expense | $k | [122](/filings/0001493152-24-045153.md) | [126 d](/filings/0001641172-25-001238.md) | [130](/filings/0001641172-25-010985.md) | [131](/filings/0001493152-25-011968.md) | [133](/filings/0001493152-25-021953.md) | [136 d](/filings/0001493152-26-013630.md) | [140](/filings/0001493152-26-023130.md) | [142](/filings/0001493152-26-037818.md) | [144](/filings/0001493152-25-021953.md) | [144 d](/filings/0001493152-26-013630.md) | [148](/filings/0001493152-26-023130.md) | [151](/filings/0001493152-26-037818.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(549)](/filings/0001493152-24-045153.md) | [(1,325) d](/filings/0001641172-25-001238.md) | [(508)](/filings/0001641172-25-010985.md) | [(1,606)](/filings/0001493152-25-011968.md) | [(433)](/filings/0001493152-25-021953.md) | [(852) d](/filings/0001493152-26-013630.md) | [(600)](/filings/0001493152-26-023130.md) | [(726)](/filings/0001493152-26-037818.md) | [(1,510)](/filings/0001493152-25-021953.md) | [(788) d](/filings/0001493152-26-013630.md) | [(943)](/filings/0001493152-26-023130.md) | [(910)](/filings/0001493152-26-037818.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001493152-24-045153.md) | not reported | [0.00](/filings/0001641172-25-010985.md) | [0.00](/filings/0001493152-25-011968.md) | [0.00](/filings/0001493152-25-021953.md) | not reported | [0.00](/filings/0001493152-26-023130.md) | [0.00](/filings/0001493152-26-037818.md) | [0.00](/filings/0001493152-25-021953.md) | not reported | [0.00](/filings/0001493152-26-023130.md) | [0.00](/filings/0001493152-26-037818.md) |
| Basic EPS | $ per share | [0.00](/filings/0001493152-24-045153.md) | not reported | [0.00](/filings/0001641172-25-010985.md) | [0.00](/filings/0001493152-25-011968.md) | [0.00](/filings/0001493152-25-021953.md) | not reported | [0.00](/filings/0001493152-26-023130.md) | [0.00](/filings/0001493152-26-037818.md) | [0.00](/filings/0001493152-25-021953.md) | not reported | [0.00](/filings/0001493152-26-023130.md) | [0.00](/filings/0001493152-26-037818.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.9](/filings/0001493152-23-040575.md) | [2.6](/filings/0001641172-25-001238.md) | [2.0](/filings/0001493152-24-019270.md) | [1.5](/filings/0001493152-24-032266.md) | [1.2](/filings/0001493152-24-045153.md) | [0.7](/filings/0001493152-26-013630.md) | [0.4](/filings/0001641172-25-010985.md) | [0.8](/filings/0001493152-25-011968.md) | [1.6](/filings/0001493152-25-021953.md) | [1.8](/filings/0001493152-26-037818.md) | [2.9](/filings/0001493152-26-023130.md) | [3.4](/filings/0001493152-26-037818.md) |
| Current assets | $m | [3.0](/filings/0001493152-23-040575.md) | [2.6](/filings/0001641172-25-001238.md) | [2.1](/filings/0001493152-24-019270.md) | [1.5](/filings/0001493152-24-032266.md) | [1.2](/filings/0001493152-24-045153.md) | [0.7](/filings/0001493152-26-013630.md) | [0.5](/filings/0001641172-25-010985.md) | [0.8](/filings/0001493152-25-011968.md) | [1.6](/filings/0001493152-25-021953.md) | [1.9](/filings/0001493152-26-037818.md) | [3.0](/filings/0001493152-26-023130.md) | [3.6](/filings/0001493152-26-037818.md) |
| Total assets | $m | [3.6](/filings/0001493152-23-040575.md) | [3.2](/filings/0001641172-25-001238.md) | [2.8](/filings/0001493152-24-019270.md) | [2.2](/filings/0001493152-24-032266.md) | [2.0](/filings/0001493152-24-045153.md) | [1.5](/filings/0001493152-26-013630.md) | [1.3](/filings/0001493152-26-023130.md) | [1.6](/filings/0001493152-26-037818.md) | [2.4](/filings/0001493152-25-021953.md) | [2.6](/filings/0001493152-26-037818.md) | [3.7](/filings/0001493152-26-023130.md) | [4.3](/filings/0001493152-26-037818.md) |
| Current liabilities | $m | [8.6](/filings/0001493152-23-040575.md) | [8.9](/filings/0001641172-25-001238.md) | [9.0](/filings/0001493152-24-019270.md) | [9.1](/filings/0001493152-24-032266.md) | [9.3](/filings/0001493152-24-045153.md) | [9.6](/filings/0001493152-26-013630.md) | [9.8](/filings/0001641172-25-010985.md) | [10.0](/filings/0001493152-25-011968.md) | [10.2](/filings/0001493152-25-021953.md) | [10.4](/filings/0001493152-26-037818.md) | [10.7](/filings/0001493152-26-023130.md) | [10.9](/filings/0001493152-26-037818.md) |
| Total liabilities | $m | [8.6](/filings/0001493152-23-040575.md) | [8.9](/filings/0001641172-25-001238.md) | [9.0](/filings/0001493152-24-019270.md) | [9.2](/filings/0001493152-24-032266.md) | [9.4](/filings/0001493152-24-045153.md) | [9.7](/filings/0001493152-26-013630.md) | [9.9](/filings/0001641172-25-010985.md) | [10.1](/filings/0001493152-25-011968.md) | [10.3](/filings/0001493152-25-021953.md) | [10.6](/filings/0001493152-26-037818.md) | [10.8](/filings/0001493152-26-023130.md) | [11.0](/filings/0001493152-26-037818.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(5.0)](/filings/0001493152-24-045153.md) | [(5.7)](/filings/0001493152-26-013630.md) | [(6.2)](/filings/0001493152-25-011968.md) | [(7.0)](/filings/0001493152-25-021953.md) | [(7.4)](/filings/0001493152-25-021953.md) | [(8.1)](/filings/0001493152-26-037818.md) | [(8.5)](/filings/0001493152-26-037818.md) | [(8.5)](/filings/0001493152-26-037818.md) | [(8.0)](/filings/0001493152-25-021953.md) | [(8.0)](/filings/0001493152-26-037818.md) | [(7.1)](/filings/0001493152-26-037818.md) | [(6.8)](/filings/0001493152-26-037818.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(249) d](/filings/0001493152-24-045153.md) | [(328) d](/filings/0001641172-25-001238.md) | [(490)](/filings/0001641172-25-010985.md) | [(511) d](/filings/0001493152-25-011968.md) | [(326) d](/filings/0001493152-25-021953.md) | [(513) d](/filings/0001493152-26-013630.md) | [(434)](/filings/0001493152-26-023130.md) | [(443) d](/filings/0001493152-26-037818.md) | [(462) d](/filings/0001493152-25-021953.md) | [(449) d](/filings/0001493152-26-013630.md) | [(530)](/filings/0001493152-26-023130.md) | [(599) d](/filings/0001493152-26-037818.md) |
| Capital expenditure | $k | not reported | [0.0 d](/filings/0001641172-25-001238.md) | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001493152-25-021953.md) | [1.6 d](/filings/0001493152-26-013630.md) | [14.1](/filings/0001493152-26-023130.md) | [28.6 d](/filings/0001493152-26-037818.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [977](/filings/0001493152-23-040575.md) | [1,032](/filings/0001493152-24-019270.md) | [1,033](/filings/0001493152-24-032266.md) | [1,033](/filings/0001493152-24-045153.md) | [1,038](/filings/0001641172-25-010985.md) | [1,038](/filings/0001493152-25-011968.md) | [1,038](/filings/0001493152-25-021953.md) | [1,041](/filings/0001493152-26-023130.md) | [1,047](/filings/0001493152-26-037818.md) | [1,068](/filings/0001493152-25-021953.md) | [1,091](/filings/0001493152-26-023130.md) | [1,110](/filings/0001493152-26-037818.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,099,791,733 at 2026-03-30, from the cover of the [10-K filed 2026-03-30](/filings/0001493152-26-013630.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.